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Hence, in 275 episodes of fungemia ini-
tially reported as caused by a yeast, 30
(11%) involved either Candida species
with a high minimum inhibitory concen-
tration for echinocandins (5), a non-Can-
dida opportunistic yeast (23), or pseu-
doyeast (7). We need prospective, mul-
ti-institutional studies to capture the
prevalence of echinocandin-nonsuscepti-
ble Candida species and non-Candida
yeasts. Finally, although it is unclear
whether starting with an echinocandin for
treatment of these patient is associated
with inferior outcomes, further studies are
needed to evaluate the impact of echin-
ocandin-based preemptive therapy for
that subset of patients.
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Reply to Kontoyiannis
To the Editor—We appreciate the com-
ments of Dr. Kontoyiannis [1] relating to
the recently updated Infectious Diseases
Society of America treatment guidelines
for invasive candidiasis [2]. It is easy to
understand his perspective, which repre-
sents that of someone who almost exclu-
sively treats severely immunosuppressed
individuals. Let us briefly comment on the
2 issues that he raises: (1) the applicability
of findings from large, randomized can-
didemia treatment studies to highly im-
munosuppressed patients, including
those with neutropenia, and (2) the ini-
tial approach to antifungal therapy in this
patient population with yeast in the
bloodstream.
To address the first point, we agree that
the numerous prospective, randomized
trials for the treatment of candidemia have
generally not enrolled significant numbers
of neutropenic patients, stem cell trans-
plant recipients, or other severely immu-
nocompromised patients. In the earliest of
these studies, neutropenic patients were
specifically excluded from enrollment into
these trials because it was believed that
their outcomes might not necessarily re-
flect those of nonneutropenic patients and
that adding this element of heterogeneity
might further confound the interpretation
of study results [3, 4]. Subsequent studies
have allowed enrollment of neutropenic
patients, but these patients still constitute
a very small proportion of the total en-
rollment [5–7]. As an example, in the larg-
est of these recent studies, only ∼10% of
eligible patients were neutropenic at base-
line [7]. Interestingly, the overall success
seen in the neutropenic patients was sim-
ilar to that seen in nonneutropenic pa-
tients. Still, these data do not sufficiently
address the issue of optimal therapy for
invasive candidiasis in the highly immu-
nosuppressed patient. The obvious answer
to this conundrum is to design and con-
duct a properly powered randomized trial
comparing different therapies for an ex-
clusively immunosuppressed and/or neu-
tropenic population. Unfortunately, this
has proven quite challenging. Large epi-
demiological surveys of candidemia in the
United States demonstrate that only∼10%
of all patients with candidemia are neu-
tropenic [8]. Because of this reality, to con-
duct a candidemia treatment trial involv-
ing exclusively neutropenic patients has
been considered unfeasible if one uses
conventional methods of determining el-
igibility (ie, positive culture of blood or
specimen from an ordinarily sterile site).
For the moment, we are left to make the
best of the limited data that are available
from small numbers of these patients in
randomized clinical trials, nonrandomi-
zed studies, and our collective clinical
experience.
The second issue is equally difficult to
address: how does one approach the neu-
tropenic or severely immunosuppressed
patient with fungemia due to non-Can-
dida yeasts? Kontoyiannis correctly points
out that non-Candida yeasts may account
for up to 10% of all bloodstream yeast
isolates in selected centers, but how com-
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monly does this occur in the most centers?
We simply do not have these data. From
our perspective, this most important point
emphasizes the need for constant vigilance
in this area. We agree that less common
yeasts can be important pathogens in these
highly vulnerable patients and that any
empirical choice for antifungal therapy
may prove to be inadequate (eg, giving an
echinocandin to treat Cryptococcus neo-
formans infection) for a particular heavily
immunosuppressed patient with yeast in
the bloodstream. Unfortunately, no single
choice of an antifungal agent adequately
addresses each of the possible pathogens.
Fortunately, the recent development of
early diagnostic techniques (eg, fluores-
cence in situ hybridization using peptide
nucleic acid probes) that are able to reli-
ably identify organisms as Candida spe-
cies could soon make antifungal selec-
tion more targeted.
Finally, it is important to recognize the
limitations of treatment guidelines in gen-
eral. They are never intended to address
every clinical situation, nor can they. Their
main intent is to espouse the most reason-
able and accepted treatment approaches,
based on available data, for the more com-
mon and easily defined manifestations of a
particular infectious process. With this in
mind, we greatly value the perspective of
those whose opinions differ from those of-
fered in these guidelines.
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Cefepime and All-Cause
Mortality
To the Editor—We are grateful to
Nguyen et al [1] for rising to the challenge
and tackling the question of whether we
should continue using cefepime. The pri-
mary outcome in our meta-analysis was
all-cause mortality [2]. We did not use
infection-related mortality as did Sanz et
al [3]. When all-cause mortality data were
not given in a published trial, we contacted
the authors of that trial and asked for 30-
day all-cause mortality data by intention
to treat, as in Gomez et al [4]. Of note,
copies of these letters were always sent
to the pharmaceutical companies that
funded these trials, but they were not an-
swered, even after presentation of prelim-
inary results [5]. Correspondence is avail-
able on request.
Prevention of death is the main goal of
treating patients with sepsis. Assigning the
direct cause of death for patients with sep-
sis is difficult or impossible, even with
postmortem examinations [6–9]. Thus,
infection-related mortality may not be re-
liable and can be biased. We wanted to
capture all deaths, including those related
to adverse events, superinfections, and
Clostridium difficile infection. Complete-
ly unrelated causes should have been
equally distributed between trial arms.
Clinical and microbiological success may
not be reliable; these are nonrandomized
comparisons applied to a subgroup of as-
sessable patients, using a poorly defined
outcome.
Nguyen et al [1] raised the issue of con-
founders, both during a trial and between
trials. Bow et al [10] used adequate ran-
domization methods (central randomi-
zation and computer-generated sequenc-
ing), resulting in equal distribution of the
risk factors related to mortality between
the study groups. In our meta-analysis, in
which we combined effects (not individ-
uals), the main confounder considered
was the comparator antibiotic. Visually
and statistically, there was no heteroge-
neity between trials in the analysis for
mortality (risk ratio, 1.26; 95% confidence
interval, 1.08–1.49; ).2I p 0%
Three explanations for the difference in
all-cause mortality might be examined.
